effect evaluation of critical formulation variables of “metered dose inhaler” using 2^3 full...

5
FOR SUSPENSION AEROSOL DEVELOPMENT AS PER QbD EFFECT EVALUATION OF CRITICAL FORMULATION VARIABLES OF METERED DOSE INHALER INADEQUATE DRUG RELEASE PER SINGLE ACTUATION EFFICACY COMPROMISED 3 LEVEL FACTORIAL PLACKETTE BURMAN 2 LEVEL FULL FACTORIAL MIXTURE RESPONSE SURFACE FACTORIAL EVALUATION OF CRITICAL FACTORS ANALYSIS OF RESPONSE DESIGNING OF EXPERIMMENTS IDENTIFICATION OF FACTORS B SUSPENDING AGENT C PROPELLANT CONTENT CASE STUDY 6 © Created & Copyrighted by Shivang Chaudhary SHIVANG CHAUDHARY Created & Copyrighted by: Quality Risk Manager & Intellectual Property Sentinel- CIIE, IIM Ahmedabad, INDIA MS Pharm (Pharmaceutics)-NIPER, PGD (Patents Law)-NALSAR [email protected] API PARTICLE SIZE A RISKS

Upload: shivang-chaudhary

Post on 09-Aug-2015

95 views

Category:

Healthcare


1 download

TRANSCRIPT

FOR SUSPENSION AEROSOL DEVELOPMENT AS PER QbD

EFFECT EVALUATION OF CRITICAL FORMULATION VARIABLES OF METERED DOSE INHALER

INADEQUATE DRUG RELEASE PER SINGLE ACTUATION

EFFICACY COMPROMISED

3 LEVEL FACTORIAL

PLACKETTE BURMAN

2 LEVEL FULL FACTORIAL

MIXTURE RESPONSE SURFACE FACTORIAL

EVALUATION OF CRITICAL FACTORS

ANALYSIS OF RESPONSE

DESIGNING OF EXPERIMMENTS

IDENTIFICATION OF FACTORS

B SUSPENDING AGENT

C PROPELLANT CONTENT

CA

SE

STU

DY

6

© Created & Copyrighted by Shivang Chaudhary

SHIVANG CHAUDHARY Created & Copyrighted by:

Quality Risk Manager & Intellectual Property Sentinel- CIIE, IIM Ahmedabad, INDIA MS Pharm (Pharmaceutics)-NIPER, PGD (Patents Law)-NALSAR

[email protected]

API PARTICLE SIZE A

RISKS

IDENTIFICATION OF FACTORS

Factors (Variables) Levels of Factors studied -1 +1

A API PARTICLE SIZE (microns) 1 10 B SUSPENDING AGENT (%w/w) 0.10 0.80 C PROPELLANT (%w/w) 70 90

NO. OF FACTORS

NO. OF LEVELS

EXPERIMENTAL DESIGN SELECTED

TOTAL NO OF EXPERIMENTAL RUNS (NO OF TRIALS)

3

2

23 FULL FACTORIAL DESIGN

23

= 8

OBJECTIVE To Evaluate the Effects of Critical Formulation Variables of Metered Dose Inhaler (Suspension Aerosols))

EVALUATION OF CRITICAL FACTORS

ANALYSIS OF RESPONSE

DESIGNING OF EXPERIMMENTS

3 LEVEL FACTORIAL

PLACKETTE BURMAN

2 LEVEL FULL FACTORIAL

EFFECT EVALUATION OF CRITICALFORMULATION VARIABLES OF METERED DOSE INHALER (SUSPENSION AEROSOLS)

MIXTURE RESPONSE SURFACE FACTORIAL

A API PARTICLE SIZE

C

PR

OP

ELL

AN

T

CA

SE

STU

DY

6

© Created & Copyrighted by Shivang Chaudhary

IDENTIFICATION OF FACTORS

CQA CMAs

PREDICTION EFFECT EQUATION OF EACH FACTOR & THEIR INTERACTIONS ON INDIVIDUAL RESPONSE BY LINEAR MODEL

NET CONTENT OF DRUG PER DISCHARGE FROM MDI= +89.20 -8.18A +3.13B +1.67C +1.45AB +0.55AC -0.45BC + 0.025ABC

EFFECT EVALUATION OF CRITICALFORMULATION VARIABLES OF METERED DOSE INHALER (SUSPENSION AEROSOLS)

EVALUATION OF CRITICAL FACTORS

DESIGNING OF EXPERIMMENTS

3 LEVEL FACTORIAL

PLACKETTE BURMAN

2 LEVEL FULL FACTORIAL

ANALYSIS OF RESPONSE

MIXTURE RESPONSE SURFACE FACTORIAL C

ASE

ST

UD

Y 6

© Created & Copyrighted by Shivang Chaudhary

IDENTIFICATION OF FACTORS

DESIGNING OF EXPERIMMENTS

Responses (Effects) Goals for Individual Responses Y1 %Net Content Per Discharge From MDI To achieve NLT 90% drug discharge per single actuation

SIGNIFICANT EFFECTS: MODEL TERMS

EFFECT EVALUATION OF CRITICALFORMULATION VARIABLES OF METERED DOSE INHALER (SUSPENSION AEROSOLS)

ANALYSIS OF RESPONSE

3 LEVEL FACTORIAL

PLACKETTE BURMAN

2 LEVEL FULL FACTORIAL

EVALUATION OF CRITICAL FACTORS

MIXTURE RESPONSE SURFACE FACTORIAL C

ASE

ST

UD

Y 6

NET CONTENT OF DRUG PER DISCHARGE FROM MDI= +89.20 -8.18A +3.13B +1.67C +1.45AB

© Created & Copyrighted by Shivang Chaudhary

THANK YOU SO MUCH FROM

DESIGN IS A JOURNEY OF DISCOVERY…

© Created & Copyrighted by Shivang Chaudhary

SHIVANG CHAUDHARY

© Copyrighted by Shivang Chaudhary

Quality Risk Manager & Intellectual Property Sentinel- CIIE, IIM Ahmedabad MS (Pharmaceutics)- National Institute of Pharmaceutical Education & Research (NIPER), INDIA

PGD (Patents Law)- National academy of Legal Studies & Research (NALSAR), INDIA

+91 -9904474045, +91-7567297579 [email protected]

https://in.linkedin.com/in/shivangchaudhary

facebook.com/QbD.PAT.Pharmaceutical.Development